The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Open accessAbstract
A main challenge in realizing the full potential of nucleic acid therapeutics is efficient delivery of them into targeted tissues and cells. N-acetylgalactosamine (GalNAc) is a well-defined liver-targeted moiety benefiting from its high affinity with asialoglycoprotein receptor (ASGPR). By conjugating it directly to the oligonucleotides or decorating it to a certain delivery system as a targeting moiety, GalNAc has achieved compelling successes in the development of nucleic acid therapeutics in recent years. Several oligonucleotide modalities are undergoing pivotal clinical studies, followed by a blooming pipeline in the preclinical stage. This review covers the progress of GalNAc-decorated oligonucleotide drugs, including siRNAs, anti-miRs, and ASOs, which provides a panorama for this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA biogenesis: coordinated cropping and dicing
Kim, V. N. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1644 · Cited by 2,546
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Endosomal escape pathways for delivery of biologicals
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.004 · Cited by 1,561
Coated pits, coated vesicles, and receptor-mediated endocytosis
Goldstein, J. L., Anderson, R. G. W., & Brown, M. S. (1979) · Nature · doi:10.1038/279679a0 · Cited by 1,532
Ashwell, G., & Morell, A. G. (1974) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470122860.ch3 · Cited by 1,210
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Illuminating the silence: understanding the structure and function of small RNAs
Rana, T. M. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2085 · Cited by 1,083
Endocytic mechanisms for targeted drug delivery☆
BAREFORD, L., & SWAAN, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.008 · Cited by 1,033
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Receptor-mediated in vitro gene transformation by a soluble DNA carrier system.
Wu, G. Y., & Wu, C. H. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61209-8 · Cited by 855
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703778104 · Cited by 658
Receptor-mediated gene delivery and expression in vivo.
Wu, G. Y., & Wu, C. H. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68081-0 · Cited by 635
Breaking down the barriers: siRNA delivery and endosome escape
Dominska, M., & Dykxhoorn, D. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.066399 · Cited by 630
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 577
The asialoglycoprotein receptor: relationships between structure, function, and expression
Stockert, R. J. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.3.591 · Cited by 520
Lee, Y. C., Townsend, R. R., Hardy, M. R., Lönngren, J., Arnarp, J., Haraldsson, M., & Lönn, H. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33240-x · Cited by 503
The asialoglycoprotein receptor: a model for endocytic transport receptors
Spiess, M. (1990) · Biochemistry · doi:10.1021/bi00495a001 · Cited by 485
First microRNA mimic enters clinic
Bouchie, A. (2013) · Nature Biotechnology · doi:10.1038/nbt0713-577 · Cited by 472
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
Monteleone, G., Neurath, M. F., Ardizzone, S., Di Sabatino, A., Fantini, M. C., Castiglione, F., Scribano, M. L., Armuzzi, A., Caprioli, F., Sturniolo, G. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407250 · Cited by 401
Vienberg, S., Geiger, J., Madsen, S., & Dalgaard, L. T. (2017) · Acta Physiologica · doi:10.1111/apha.12681 · Cited by 373
Schwartz, A. L., Fridovich, S. E., & Lodish, H. F. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34710-0 · Cited by 364
RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
Bobbin, M. L., & Rossi, J. J. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103633 · Cited by 353
Plank, C., Zatloukal, K., Cotten, M., Mechtler, K., & Wagner, E. (1992) · Bioconjugate Chemistry · doi:10.1021/bc00018a012 · Cited by 324
Sehgal, A., Barros, S., Ivanciu, L., Cooley, B., Qin, J., Racie, T., Hettinger, J., Carioto, M., Jiang, Y., Brodsky, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3847 · Cited by 306
Stein, E. A., Dufour, R., Gagne, C., Gaudet, D., East, C., Donovan, J. M., Chin, W., Tribble, D. L., & McGowan, M. (2012) · Circulation · doi:10.1161/circulationaha.112.104125 · Cited by 301
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Wooddell, C. I., Rozema, D. B., Hossbach, M., John, M., Hamilton, H. L., Chu, Q., Hegge, J. O., Klein, J. J., Wakefield, D. H., Oropeza, C. E., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.31 · Cited by 293
RNAi and small interfering RNAs in human disease therapeutic applications
Lares, M. R., Rossi, J. J., & Ouellet, D. L. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.07.009 · Cited by 277
Human hepatic lectin. Physiochemical properties and specificity.
Baenziger, J. U., & Maynard, Y. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85538-2 · Cited by 264
Evolving landscape in the management of transthyretin amyloidosis
Hawkins, P. N., Ando, Y., Dispenzeri, A., Gonzalez-Duarte, A., Adams, D., & Suhr, O. B. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1068949 · Cited by 243
Baenziger, J. U., & Fiete, D. (1980) · Cell · doi:10.1016/0092-8674(80)90371-2 · Cited by 242
Rensen, P. C. N., Sliedregt, L. A. J. M., Ferns, M., Kieviet, E., van Rossenberg, S. M. W., van Leeuwen, S. H., van Berkel, T. J. C., & Biessen, E. A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101786200 · Cited by 231
Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro
Wu, G. Y., & Wu, C. H. (1988) · Biochemistry · doi:10.1021/bi00403a008 · Cited by 222
Matsuda, S., Keiser, K., Nair, J. K., Charisse, K., Manoharan, R. M., Kretschmer, P., Peng, C. G., V. Kel’in, A., Kandasamy, P., Willoughby, J. L. S., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb501028c · Cited by 221
Ca2+-dependent carbohydrate-recognition domains in animal proteins
Drickamer, K. (1993) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(05)80112-5 · Cited by 201
Liebow, A., Li, X., Racie, T., Hettinger, J., Bettencourt, B. R., Najafian, N., Haslett, P., Fitzgerald, K., Holmes, R. P., Erbe, D., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030338 · Cited by 201
Uptake and degradation of 125I-labelled asialo-fetuin by isolated rat hepatocytes
Tolleshaug, H. (1977) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(77)90230-6 · Cited by 189
Rajeev, K. G., Nair, J. K., Jayaraman, M., Charisse, K., Taneja, N., O'Shea, J., Willoughby, J. L. S., Yucius, K., Nguyen, T., Shulga‐Morskaya, S., et al. (2015) · ChemBioChem · doi:10.1002/cbic.201500023 · Cited by 185
Meier, M., Bider, M. D., Malashkevich, V. N., Spiess, M., & Burkhard, P. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3853 · Cited by 182
Wu, G. Y., & Wu, C. H. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42295-8 · Cited by 180
Ackermann, E. J., Guo, S., Benson, M. D., Booten, S. L., Freier, S., Hughes, S. G., Kim, T., Kwoh, T. J., Matson, J. E., Norris, D., et al. (2016) · Amyloid · doi:10.1080/13506129.2016.1191458 · Cited by 153
Synthesis of Cluster Galactosides with High Affinity for the Hepatic Asialoglycoprotein Receptor
Biessen, E. A. L., Beuting, D. M., Roelen, H. C. P. F., van der MAREL, G. A., BOOM, J. H. V., & van Berkel, T. J. C. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00009a014 · Cited by 151
Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor
Khorev, O., Stokmaier, D., Schwardt, O., Cutting, B., & Ernst, B. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.03.017 · Cited by 147
Parmar, R. G., Willoughby, J. L. S., Liu, J., Foster, D. J., Brigham, B., Theile, C. S., Charissé, K., Akinc, A., Guidry, E. N., Pei, Y., et al. (2016) · ChemBioChem · doi:10.1002/cbic.201600130 · Cited by 146
Pol, S., & Lampertico, P. (2012) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2012.01602.x · Cited by 144
Yasuda, M., Gan, L., Chen, B., Kadirvel, S., Yu, C., Phillips, J. D., New, M. I., Liebow, A., Fitzgerald, K. J., Querbes, W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406228111 · Cited by 133
Fred Saad, C., Hotte, S. J., North, S. A., Eigl, B. J., Chi, K., Czaykowski, P., Wood, L. A., Pollak, M., Berry, S. R., Lattouf, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0859 · Cited by 132
Prakash, T. P., Yu, J., Migawa, M. T., Kinberger, G. A., Wan, W. B., Østergaard, M. E., Carty, R. L., Vasquez, G., Low, A., Chappell, A. E., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01948 · Cited by 132
Chan, A., Liebow, A., Yasuda, M., Gan, L., Racie, T., Maier, M., Kuchimanchi, S., Foster, D., Milstein, S., Charisse, K., et al. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.36 · Cited by 128
Steirer, L. M., Park, E. I., Townsend, R. R., & Baenziger, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m808689200 · Cited by 128
Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte.
Schwartz, A. L., Rup, D., & Lodish, H. F. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70522-5 · Cited by 125
Inhibition of Coagulation by a Phosphorothioate Oligonucleotide
Henry, S. P., Novotny, W. F., LEEDS, J., Auletta, C. S., & Kornbrust, D. J. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.503 · Cited by 122
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis
Butler, J. S., Chan, A., Costelha, S., Fishman, S., Willoughby, J. L. S., Borland, T. D., Milstein, S., Foster, D. J., Gonçalves, P., Chen, Q., et al. (2016) · Amyloid · doi:10.3109/13506129.2016.1160882 · Cited by 113
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic
Moreno, P. M. D., & Pêgo, A. P. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00087 · Cited by 111
The binding site of rabbit hepatic lectin.
Sarkar, M., Liao, J., Kabat, E. A., Tanabe, T., & Ashwell, G. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50739-0 · Cited by 105
Wong, S. C., Klein, J. J., Hamilton, H., Chu, Q., Frey, C. L., Trubetskoy, V. S., Hegge, J., Wakefield, D. H., Rozema, D. B., & Lewis, D. L. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0389 · Cited by 101
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
Yu, R. Z., Graham, M. J., Post, N. M., Riney, S., Zanardi, T. A., Hall, S., Burkey, J., Shemesh, C. S., Prakash, T. P., Seth, P. P., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.26 · Cited by 97
Merwin, J. R., Noell, G. S., Thomas, W. L., Chiou, H. C., DeRome, M., McKee, T. D., Spitalny, G. L., & Findeis, M. A. (1994) · Bioconjugate Chemistry · doi:10.1021/bc00030a017 · Cited by 93
Solano, E. C. R., Kornbrust, D. J., Beaudry, A. A., Foy, J. W.-D., Schneider, D. J., & Thompson, J. D. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0489 · Cited by 91
Iobst, S. T., & Drickamer, K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.12.6686 · Cited by 91
Aiming for cure in HBV and HDV infection
Petersen, J., Thompson, A. J. V., & Levrero, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.043 · Cited by 91
Rensen, P. C. N., van Leeuwen, S. H., Sliedregt, L. A. J. M., van Berkel, T. J. C., & Biessen, E. A. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049481d · Cited by 87
Efficient Synthesis and Biological Evaluation of 5′-GalNAc Conjugated Antisense Oligonucleotides
Østergaard, M. E., Yu, J., Kinberger, G. A., Wan, W. B., Migawa, M. T., Vasquez, G., Schmidt, K., Gaus, H. J., Murray, H. M., Low, A., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00265 · Cited by 82
Pallan, P. S., Allerson, C. R., Berdeja, A., Seth, P. P., Swayze, E. E., Prakash, T. P., & Egli, M. (2012) · Chemical Communications · doi:10.1039/c2cc32286b · Cited by 79
Intracellular localization and degradation of asialofetuin in isolated rat hepatocytes
Tolleshaug, H., Berg, T., Frølich, W., & Norum, K. R. (1979) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(79)90326-x · Cited by 72
Retrospective study of a TTR FAP cohort to modify NIS + 7 for therapeutic trials
Suanprasert, N., Berk, J. L., Benson, M. D., Dyck, P. J. B., Klein, C. J., Gollob, J., Bettencourt, B. R., Karsten, V., & Dyck, P. J. B. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.06.041 · Cited by 70
2017 Clinical trials update in new treatments of β‐thalassemia
Makis, A. C., Hatzimichael, E. C., Papassotiriou, I., & Voskaridou, E. (2016) · American Journal of Hematology · doi:10.1002/ajh.24530 · Cited by 67
Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line
Dowling, J. J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.180 · Cited by 67
Hangeland, J. J., Levis, J. T., Lee, Y. C., & Ts’o, P. O. P. (1995) · Bioconjugate Chemistry · doi:10.1021/bc00036a006 · Cited by 63
Shemesh, C. S., Yu, R. Z., Gaus, H. J., Greenlee, S., Post, N. M., Schmidt, K., Migawa, M. T., Seth, P. P., Zanardi, T. A., Prakash, T. P., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.31 · Cited by 62
Prakash, T. P., Kinberger, G. A., Murray, H. M., Chappell, A. E., Riney, S., Graham, M. J., Lima, W. F., Swayze, E. E., & Seth, P. P. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.063 · Cited by 55
Targeted In Vivo Delivery of siRNA and an Endosome-Releasing Agent to Hepatocytes
Sebestyén, M. G., Wong, S. C., Trubetskoy, V. S., Lewis, D. L., & Wooddell, C. I. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1538-5_10 · Cited by 50
Anti-miRs Competitively Inhibit microRNAs in Argonaute Complexes
Hogan, D. J., Vincent, T. M., Fish, S., Marcusson, E. G., Bhat, B., Chau, B. N., & Zisoulis, D. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100951 · Cited by 50
Yamamoto, T., Sawamura, M., Wada, F., Harada‐Shiba, M., & Obika, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.11.036 · Cited by 49
Progress and Prospects of Anti-HBV Gene Therapy Development
Maepa, M. B., Roelofse, I., Ely, A., & Arbuthnot, P. B. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817589 · Cited by 45
Kinberger, G. A., Prakash, T. P., Yu, J., Vasquez, G., Low, A., Chappell, A. E., Schmidt, K., Murray, H. M., Gaus, H. J., Swayze, E. E., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.05.084 · Cited by 43
Protease-triggered siRNA delivery vehicles
Rozema, D. B., Blokhin, A. V., Wakefield, D. H., Benson, J. D., Carlson, J. C., Klein, J. J., Almeida, L., Nicholas, A. L., Hamilton, H., Chu, Q., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.012 · Cited by 40
Monteleone, G., Sabatino, A. D., Ardizzone, S., Pallone, F., Usiskin, K., Zhan, X., Rossiter, G., & Neurath, M. F. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13526 · Cited by 36
Biessen, E. A. L., Sliedregt, K., Hoen, P. A. C. ’., Prince, P., van de Bilt, E., Valentijn, A. R. P. M., Meeuwenoord, N. J., Princen, H. M. G., Bijsterbosch, M. K., van der MAREL, G. A., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc015550g · Cited by 35
Current and future medical treatments for patients with acromegaly
Maffezzoni, F., Formenti, A. M., Mazziotti, G., Frara, S., & Giustina, A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1199687 · Cited by 34
Lee, D. U., Huang, W., Rittenhouse, K. D., & Jessen, B. A. (2012) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2011.0116 · Cited by 29
Lactosaminated human albumin, a hepatotropic carrier of drugs
FIUME, L., & Stefano, G. D. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.04.004 · Cited by 28
Prakash, T. P., Wan, W. B., Low, A., Yu, J., Chappell, A. E., Gaus, H. J., Kinberger, G. A., Østergaard, M. E., Migawa, M. T., Swayze, E. E., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.08.019 · Cited by 27
Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities
Bouclé, S., Bassit, L., Ehteshami, M., & Schinazi, R. F. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.07.001 · Cited by 27
Novel therapies for severe dyslipidemia originating from human genetics
Gaudet, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000281 · Cited by 18
Development of Antisense Drugs for Dyslipidemia
Yamamoto, T., Wada, F., & Harada‐Shiba, M. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16001 · Cited by 18
Emerging drugs for the treatment of hemophilia A and B
Morfini, M., & Zanon, E. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220536 · Cited by 17
Hill, A., Täubel, J., Bush, J. A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.2413.2413 · Cited by 16
Rohlff, C., Watson, S. A., Morris, T. M., Skelton, L., Jackman, A. L., & Pagé, M. (1999) · PubMed · Cited by 13
Sehgal, A., Blomenkamp, K., Qian, K., Simon, A. R., Haslett, P. A. J., Barros, S. A., & Teckman, J. H. (2015) · Gastroenterology · doi:10.1016/s0016-5085(15)33331-x · Cited by 11
NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY.
Strat, A. L., Ghiciuc, C. M., Lupușoru, C. E., & Mitu, F. (2016) · The Medical-Surgical Journal · Cited by 11
Migawa, M. T., Prakash, T. P., Vasquez, G., Wan, W. B., Yu, J., Kinberger, G. A., Østergaard, M. E., Swayze, E. E., & Seth, P. P. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.070 · Cited by 9
Drug developers refocus efforts on RAS
Sheridan, C. (2016) · Nature Biotechnology · doi:10.1038/nbt0316-217 · Cited by 8
Carney, E. F. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.123 · Cited by 3
Viney, N., Marcovina, S., Xia, S., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(16)32082-4 · Cited by 2
Cited by
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Self-citationEmerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813279 · Cited by 827
GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics
Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Metadata
- Authors
- Huang, Y.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 6
- Pages
- 116-132
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W2563642244
- Cited by
- 291
- References
- 102
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.